Introduction
Immunoglobulin (Ig) light-chain amyloidosis (AL amyloidosis) and Ig heavy-chain amyloidosis (AH amyloidosis) are both Ig-related amyloidosis caused mainly by plasma cell neoplasms. Clonal plasma cells secrete monoclonal Ig, free light-chain and truncated heavy chain, with or without structural abnormalities.
1,2 Among these, AL amyloidosis is caused by the deposition of light-chain fragment-derived amyloid fibrils, and AH amyloidosis is caused by the deposition of heavy-chain fragment-derived amyloid. Systemic AL amyloidosis is the most common type of systemic amyloidosis and accounts for approximately two-thirds of all systemic amyloidosis cases, 3 whereas systemic AH amyloidosis is a rare disease and only 17 cases have been reported. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Both types of Igrelated amyloidosis frequently affect the kidney. However, compared with patients with AL amyloidosis, those with AH amyloidosis have a favourable prognosis because of the less frequent cardiac involvement, 14 which is the leading cause of death in AL amyloidosis. Thus, the differential diagnosis between AH and AL amyloidosis is important for clinical management and therapeutic strategies.
The diagnosis of amyloidosis is based on histopathological findings. After the histopathological confirmation of amyloid deposition, the typing of the amyloid protein is essential for management of the patients. Amyloid A (AA)-, transthyretin-and beta2-microglobulin-derived amyloid can be detected readily with immunohistochemistry. However, immunohistochemical detection of AL amyloid deposition is difficult because the Ig light-chain variable region has extreme diversity and the length of the constant region included in AL amyloid deposition varies. 16, 17 Some useful antibodies have been reported, but reliable and commercially available antibodies are still limited. 18 Moreover, immunohistochemical detection of AH amyloid deposition is also difficult because AH amyloid protein often lacks the Fc portion, which is recognised by most antibodies reacting with Ig heavy chains.
1 Therefore, biochemical analyses, such as amino acid sequence analysis of extracted amyloid proteins, laser micro-dissection and mass spectrometry (LMD/MS), and liquid chromatography-tandem mass spectrometry (LC-MS/MS), are frequently required for the definite diagnosis of AH amyloidosis. 1, 5, 5, [9] [10] [11] [12] [13] [14] [15] However, these analyses are not widely available.
To detect amyloid deposition in patients with systemic amyloidosis, biopsies of abdominal adipose tissue, bone marrow and gastrointestinal (GI) tract are performed frequently due to their safety and high detection rate. The detection sensitivity of AL amyloid deposition in abdominal adipose tissue, bone marrow and GI tract are reported as approximately 90, 19 
60
20 and 50-100%, 19, [21] [22] [23] [24] [25] respectively. However, the detection sensitivity of AH amyloid deposition with abdominal adipose tissue and bone marrow is low, reported as 15 and 40%, respectively.
14 Moreover, there is no report evaluating AH amyloid deposition in the GI tract. We have reported previously the detailed histopathological findings from a systemic AH amyloidosis patient. 26 In this patient, amyloid deposition was found in the glomeruli of kidneys, mucosa of the GI tract, endocrine organs and choroid plexus, with a characteristic deposition pattern of capillary wall predominance. This capillary-predominant deposition pattern in the GI tract is not common in AL amyloidosis. Therefore, we assumed that gastroduodenal biopsy may be useful to detect AH amyloid deposition.
In this study, we examined the usefulness of gastroduodenal biopsy for the detection of AH amyloid deposition using three cases of biochemically confirmed AH amyloidosis. [9] [10] [11] In addition, we assessed whether gastroduodenal biopsy specimens are useful for the differential diagnosis between AH and AL amyloidosis using gastroduodenal biopsy specimens of 21 cases of immunohistochemically confirmed AL amyloidosis.
Materials and methods

P A T I E N T S
AH amyloidosis patients Three patients with AH amyloidosis (AH 1-3) who underwent gastroduodenal biopsy in Shinshu University Hospital from 2002 to 2015 were identified. All patients were confirmed to exhibit monoclonal immunoglobulin components by serum and/or urine immunofixation electrophoresis. Amyloid deposition was confirmed by Congo red staining. All these specimens were evaluated immunohistochemically with commercially available antibodies (anti-AA, anti-fibrinogen, anti-beta2-microglobulin and anti-transthyretin antibodies) and polyclonal antibodies against Igj [rabbit sera immunised with short peptide of the constant-region, amino acids 116-133; anti-j (116-133)] and Igk [rabbit sera immunised with short peptide of the constant-region, amino acids 118-134; anti-k (118-134)] light chain (kindly provided by Dr Yoshinobu Hoshii, Yamaguchi University, Ube, Japan), 16 and all yielded negative results. The definite diagnosis of AH amyloidosis was confirmed by amino acid sequence analysis of extracted amyloid proteins (two cases: AH 1 and 2) or by LC-MS/MS (one case: AH 3). [9] [10] [11] There was no evidence of immunoglobulin light chain in the amino acid sequence analysis or in the LC-MS/MS analysis in all three patients.
AL amyloidosis patients
Eight consecutive patients with ALj amyloidosis (ALj 1-8) and 13 consecutive patients with ALk amyloidosis (ALk 1-13) who underwent gastroduodenal biopsy at Shinshu University Hospital from 2012 to 2015 and 2014 to 2015, respectively, were identified. All patients were confirmed to exhibit monoclonal immunoglobulin components by serum and/or urine immunofixation electrophoresis. Amyloid deposition was confirmed by Congo red staining. All these specimens were evaluated immunohistochemically with commercially available antibodies (anti-AA, anti-fibrinogen, anti-beta2-microglobulin and anti-transthyretin antibodies) and all yielded negative results. ALj amyloidosis was confirmed by immunohistochemistry with anti-j (116-133) antibodies 16 and anti-human kappa light-chain antibodies (clone H16-E, ready-to-use; DB Biotech, Kosice, Slovak Republic), 18 and ALk amyloidosis was confirmed by immunohistochemistry with anti-k (118-134) antibodies. 16 These antibodies against AL amyloid fibrils have been reported to exhibit high specificity and reactivity, 16, 18 and the utility has been established. 27 T I S S U E S A M P L E S Most of the patients described above underwent gastroduodenal biopsy several times before and after treatment. The specimens before treatment for each 
Amyloid deposition was evaluated in each layer of the gastroduodenal wall: lamina propria mucosa, muscularis mucosa and submucosa. Furthermore, duodenal lamina propria mucosa was divided into two areas, villus and non-villus. Amyloid deposition was confirmed by Congo red-staining in bright field and under polarised light, and estimated semi-quantitatively according to the following criteria: 4+ (amyloid deposition was identifiable using 94 objective and 910 ocular lenses), 3+ (910 objective and 910 ocular lenses), 2+ (920 objective and 910 ocular lenses), + (940 objective and 910 ocular lenses) and À (none). All specimens were evaluated independently by two experienced pathologists (S.I. and M.K.).
I M M U N O H I S T O C H E M I S T R Y
To evaluate the histological localisation of amyloid deposition, we performed immunostaining using monoclonal antibodies for CD34 (clone QBEnd10, dilution 1:800; Beckman Coulter, Brea, CA, USA) and CD31 (clone JC/70A, dilution 1:40; Dako, Hamburg, Germany) as endothelial markers, and for type IV collagen (clone CIV 22, dilution 1:50; Dako) as a basement membrane marker. After endogenous peroxidase inhibition with 0.3% H 2 O 2 for 30 min, antigen retrieval was performed by heating sections in 0.01 M ethylenediamine tetraacetic acid (EDTA) buffer (pH 8.0) in a microwave oven at 600 W for 30 min (CD31 and CD34) or 0.05% trypsin solution in a 37°C waterbath for 60 min (type IV collagen). Incubation with primary antibodies was performed for 90 min at room temperature (CD34) or overnight at 4°C (CD31 and type IV collagen), and subsequent signal development was performed using the immunoenzyme polymer method (Histofine Simple Stain MAX PO Multi; Nichirei Biosciences, Tokyo, Japan) with 3,3 0 -diaminobenzidine as the chromogen. The sections were counterstained with haematoxylin. Surgically resected gastric mucosa and duodenal mucosa specimens obtained from a non-amyloidosis patient were used as a control of normal structures. biopsy specimens of AH amyloidosis, we performed double immunostaining and Congo red staining. After immunostaining for endothelial markers (CD31 or CD34) and a basement membrane marker (type IV collagen), Congo red staining was performed.
Results
D U O D E N A L B I O P S Y S P E C I M E N S
The representative histopathological findings are shown in Figure 1 . In AH amyloidosis, no massive or diffuse amyloid deposition was observed (Figure 1A,B) . Only a small amount of amyloid deposition was recognisable on the wall of small vessels, mainly in the submucosa in bright-field observation ( Figure 1A ). In addition, we clearly observed amyloid deposition in the villi and submucosa under polarised light ( Figure 1B,C) . Especially in the villi, dotted line-like fine amyloid deposition was seen just beneath the epithelial basement membrane (dotted line-like deposition in the villi) ( Figure 1C ). In contrast, in both ALj and ALk amyloidosis, massive and diffuse amyloid deposition, located mainly in the stroma and the small vessels of the muscuralis mucosae and submucosa, was observed (Figure 1D ,E,G,H). However, dotted line-like deposition in the villi was not identified ( Figure 1F,I ). Then, we evaluated the amyloid deposition according to the scoring system described in Materials and methods. The results are summarised in Table 1 . Both AH and AL amyloid deposition were detectable in duodenal biopsy specimens. The differences in histopathological characteristics of amyloid deposition between AH and AL amyloidosis were size, pattern and sites. First, the size and pattern of AH amyloid deposition were fine and focal (undetectable with 94 objective lens), whereas those of AL amyloid deposition were massive and sometimes diffuse (detectable with 94 objective lens in most AL amyloidosis cases). Secondly, amyloid deposition in the villi was detectable in all three AH amyloidosis cases. In contrast, AL amyloid was deposited mainly in the muscuralis mucosa and submucosa, and amyloid deposition was undetectable in the villi in most cases of AL amyloidosis even using the 940 objective lens and polarised light. Only one case of ALj amyloidosis (ALj 4) demonstrated amyloid deposition in the villi; however, its deposition pattern was massive and diffuse (detectable with 94 objective lens), distinct from that of AH amyloidosis.
As for the deposition of AH amyloid, we assumed that the histological localisation of the dotted line-like deposition in the villi was corresponding with the capillaries of the villi. Thus, we examined the histological localisation of AH amyloid deposition using serial slides with Congo red staining and immunostaining for endothelial markers. The localisation of AH amyloid deposition seemed to correspond with the wall of the capillaries in the villi (Figure 2) . Therefore, to demonstrate more exactly the association between AH amyloid deposition and the capillary structure, we performed double immunostaining and Congo red staining. With regard to the identification of capillary structure, immunohistochemistry for a basement membrane marker, type IV collagen, was also used in addition to that for endothelial markers. Representative histopathological findings are shown in Figure 3 . In double-stained specimens, amyloid deposition was identified on the wall of capillaries, which were positive for CD31 and type IV collagen ( Figure 3C,F) . From these findings, we concluded that characteristic deposition of AH amyloid in the duodenum (dotted line-like deposition in the villi) was the deposition on the wall of capillaries in the villi.
G A S T R I C B I O P S Y S P E C I M E N S
Submucosal tissue was not included in many gastric biopsy specimens; therefore, we cannot evaluate amyloid deposition in submucosa in the gastric biopsy specimens. The representative histopathological findings are shown in Figure 4 and results of amyloid deposition score are summarised in Table 2 . In both AH and AL amyloidosis, the size and pattern of amyloid deposition in gastric biopsy specimens were almost similar to those in duodenal biopsy specimens. The differences in site-specific amyloid deposition, such as dotted line-like deposition in the villi of duodenal biopsy, were not identified between AH and AL amyloidosis.
Discussion
Since Eulitz et al. 14 Thus, there may be many more cases of AH amyloidosis. Most patients with AH amyloidosis have not been recognised, and have probably been diagnosed with AL amyloidosis because both AH and AL amyloidosis are usually accompanied by plasma cell neoplasms and immunohistochemical discrimination is difficult. 16 In this study from Nasr, heavy-and light-chain amyloidosis (AHL amyloidosis) also comprised 5.0% (11 of 218 patients). As our study did not evaluate AHL amyloidosis, further investigation is needed regarding AHL amyloid deposition in gastroduodenal biopsy specimens.
Our study demonstrated the following novel histopathological findings for AH amyloidosis: (i) AH amyloid deposition was detectable in the gastroduodenal biopsy specimens and (ii) AH amyloid deposition in the duodenum exhibited the characteristic deposition pattern, dotted line-like deposition in the villi, and this feature was not observed in AL amyloidosis. In the current study, AL amyloidosis cases are thought to be more advanced than AH amyloidosis cases, comparing both amyloidosis in the size and pattern of deposition. Therefore, we felt that dotted line-like deposition in the villi was the characteristic feature of AH amyloidosis because this feature was not found in AL amyloidosis cases, which were thought to be more advanced. It is important for the detection of this characteristic AH amyloid deposition to use a high-magnification objective lens under polarised light because, in Congo red-stained specimens, small amyloid deposition is sometimes undetectable under the bright-field observation and can be identified using polarised light. 28 AA amyloidosis may also be considered from the deposition pattern alone. AA amyloidosis also exhibits amyloid deposition in the duodenal villi. 29 However, AA amyloidosis can be distinguished from AH amyloidosis both clinically and immunohistochemically. Clinically, AA amyloidosis is a secondary amyloidosis caused by chronic inflammatory disease such as rheumatoid arthritis, whereas Ig-related amyloidosis including AH amyloidosis is caused mainly by plasma cell neoplasms. Immunohistochemically, AA amyloid deposition can be detected readily.
The distribution of the characteristic dotted line-like deposition of AH amyloidosis in the duodenal villi corresponds with fenestrated capillaries, which are located mainly just beneath the absorptive epithelial cells and form a unique capillary network. These fenestrated capillary networks are present in specific tissues such as glomeruli of the kidney, choroid plexus, endocrine organs and villi of the small intestine. The distribution of fenestrated capillaries corresponds with AH amyloid deposition in our previous autopsy case. 26 In addition, the following characteristic features of AH amyloidosis can be explained clearly by the presence or absence of fenestrated capillaries: (i) predominant involvement of the kidney; (ii) improved patient prognosis due to less frequent involvement of the heart; and (iii) the lower detection sensitivity of amyloid deposition in the subcutaneous adipose tissue and bone marrow.
In the current study, we revealed that gastroduodenal biopsy can detect AH amyloid deposition, and duodenal biopsy is useful for the differential diagnosis of AH amyloidosis from AL amyloidosis. When a patient is suspected of Ig-related amyloidosis clinically, we recommend duodenal biopsy as initial examination. When dotted line-like deposition in the villi is found in duodenal biopsy specimens, further biochemical analyses are recommended for definitive diagnosis of AH amyloidosis. When the amount of the deposition is too low to perform biochemical analyses, additional biopsy from the affected site (e.g. kidney) is recommended. We can select cases that need additional invasive biopsy and further biochemical analyses only with Congo redstaining of duodenal biopsy specimens. This will lead to the accumulation of cases and improve our understanding of AH amyloidosis.
